Company Filing History:
Years Active: 2020
Title: Ives Mafli: Innovator in NEP Inhibitor Synthesis
Introduction
Ives Mafli is a prominent inventor based in Zurich, Switzerland. He has made significant contributions to the field of chemical synthesis, particularly in the development of neprilysin (NEP) inhibitors. His work is crucial for advancing therapeutic options in various medical applications.
Latest Patents
Ives Mafli holds a patent for "Processes and intermediates for NEP inhibitor synthesis." This invention relates to a new chemical synthesis, intermediates, and catalysts useful for the preparation of the neprilysin inhibitor sacubitril, among others, via nitro 5 compounds. The patent also introduces new intermediate compounds and their applications in this innovative chemical synthesis route, as well as a new catalyst ligand.
Career Highlights
Ives Mafli is currently employed at Novartis AG, a leading global healthcare company. His role involves research and development in the pharmaceutical sector, where he focuses on creating effective solutions for complex health issues. His expertise in chemical synthesis has positioned him as a valuable asset to his team and the broader scientific community.
Collaborations
Ives has collaborated with notable colleagues, including Florian Karl Kleinbeck-Riniker and Benjamin Martin. These partnerships have fostered a collaborative environment that enhances innovation and drives forward the research initiatives at Novartis AG.
Conclusion
Ives Mafli's contributions to NEP inhibitor synthesis exemplify the impact of innovative research in the pharmaceutical industry. His work not only advances scientific knowledge but also holds the potential to improve patient outcomes through new therapeutic options.